TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30321510
Drug: Nebulized Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Tranexamic Acid (500 mg tid)
Study: 21280534
Drug: 0.2 mg/ml
Normalized name: iodine 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/ml Mitomycin-C solution
Study: 21280534
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Solution
Study: 17591527
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug therapy (including ACE inhibitors and ARBs)
Study: 10221703
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (30 microg of ethinyl oestradiol and 0.15 mg of levonorgestrel per tablet)
Study: 8595506
Drug: AZT/ddI and
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT/ddI and AZT/ddC combination therapy
Study: 8595506
Drug: AZT/3TC combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT/3TC combination therapy
Study: 2242846
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (160 mg daily for 6 weeks)
Study: 1233231
Drug: Diazepam 20
Normalized name: diazePAM 20 mg rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 20 mg i.m. followed by diazepam 20 mg i.v.
Study: 1233231
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg i.m. followed by diazepam 20 mg i.v.
Study: 1233231
Drug: Pentobarbitone 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone 1 mg/kg i.m. followed by i.v. saline
Study: 1233231
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg and saline i.v.
Study: 1233231
Drug: Diazepam 20
Normalized name: diazePAM 20 mg rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 20 mg i.v.
Study: 28723227
Drug: Extended-release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release guanfacine (mean final daily dose of 2.6 ± 1.1 mg, n=14)
Study: 28723227
Drug: Extended-release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release guanfacine
Study: 25222798
Drug: Gratitude intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gratitude intervention (writing work-related gratitude diaries twice a week for 4 weeks)
Study: 25222798
Drug: Hassle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hassle intervention (writing work-related hassle diaries twice a week for 4 weeks)
Study: 25222798
Drug: Nil-treatment (no-diary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nil-treatment (no-diary group)
Study: 23802638
Drug: Sixth-generation dental
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sixth-generation dental bonding agents (DBAs)
Study: 23802638
Drug: Seventh-generation dental
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seventh-generation dental bonding agents (DBAs)
Study: 23802638
Drug: Fourth-generation dental
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth-generation dental bonding agents (DBAs)
Study: 17555901
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose Gd‐BOPTA (0.05 mmol/kg)
Study: 17056961
Drug: Scalp nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp nerve block (SNB) with 10 mL of 0.9% saline and a 1:1 mixture of bupivacaine 0.5% and lidocaine 2%
Study: 17056961
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg x kg(‐1) IV after dural closure
Study: 11099280
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole)
Study: 11099280
Drug: Conventional antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotics (usually haloperidol or chlorpromazine)
Study: 1479417
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg daily for one week (Group A)
Study: 1479417
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg daily for two weeks (Group B)
Study: 6231893
Drug: Azapropazone 600
Normalized name: Azapropazone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone 600 mg b.d.
Study: 27270841
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy (40.5°C bath for 60 min/session, 4-5 times/week for 8 weeks)
Study: 1468261
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application of betamethasone dipropionate cream and either a water-in-oil based moisturizing cream or lotion
Study: 1468261
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application of betamethasone dipropionate cream
Study: 4028806
Drug: Ketoprofen suppositories
Normalized name: ketoprofen Rectal Suppository
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen suppositories (2 X 100 mg) administered 1-hour pre-operatively
Study: 4028806
Drug: Placebo suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories administered 1-hour pre-operatively
Study: 30674296
Drug: Topical microporous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical microporous polysaccharide hemospheres (MPH) applied to the surgical site
Study: 17600880
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and etoposide with ondansetron, metoclopramide plus dexamethasone 8 mg i.v. per day for 3 days
Study: 1530141
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg, 160 mg)
Study: 1530141
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg, 20 mg)
Study: 29774635
Drug: Aripiprazole 6-12
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole 6-12 mg/day
Study: 29774635
Drug: Aripiprazole 24-30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 24-30 mg/day
Study: 29774635
Drug: Aripiprazole (OLE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (OLE, initial dose: 2 mg/day, maintenance dose: 6-24 mg/day, max 30 mg/day)
Study: 26571136
Drug: Zumba® fitness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zumba® fitness (1 to 2 classes of 1 hour weekly)
Study: 15902992
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x 5 g/d for 5 days)
Study: 14602495
Drug: Radical surgery
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical surgery followed by post-operative radiation therapy (Sx+PORT) (Arm I)
Study: 14602495
Drug: Radical radiation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiation therapy followed by salvage surgery (RRT+/‐SSx) (Arm II)
Study: 10485502
Drug: DFP 25
Normalized name: DFP
DrugBank: Isoflurophate (DB00677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFP 25 mg
Study: 10485502
Drug: DFP 50
Normalized name: DFP
DrugBank: Isoflurophate (DB00677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFP 50 mg
Study: 9245041
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) at doses of 0.015, 0.25, 1.0, 2.0 micrograms/kg/min for 20 min each
Study: 1744874
Drug: 2% polynoxylin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% polynoxylin powder applied daily to the groin and external genitalia
Study: 6803377
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics (neomycin and polymyxin)
Study: 6803377
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics (neomycin and polymyxin) plus systemic antibiotics (gentamicin and penicillin)
Study: 21463114
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance (one weekly injection for 4 weeks)
Study: 12782431
Drug: rHuEPO 10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO 10,000 U three times weekly
Study: 9471024
Drug: O1COr (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: O1COr (Omeprazole 20 mg once daily + Clarithromycin 250 mg twice daily + Ornidazole 500 mg twice daily)
Study: 9471024
Drug: OCOr (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCOr (Omeprazole 20 mg twice daily + Clarithromycin 250 mg twice daily + Ornidazole 500 mg twice daily)
Study: 9471024
Drug: OCM (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCM (Omeprazole 20 mg twice daily + Clarithromycin 250 mg twice daily + Metronidazole 500 mg twice daily)
Study: 1610161
Drug: Rice Bubbles
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice Bubbles (0.5 g/kg body weight)
Study: 1610161
Drug: Sustain (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustain (0.5 g/kg body weight)
Study: 1610161
Drug: All‐Bran (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: All‐Bran (0.5 g/kg body weight)
Study: 1610161
Drug: Porridge (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porridge (0.5 g/kg body weight)
Study: 1610161
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread (0.5 g/kg body weight)
Study: 1610161
Drug: Egg and
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg and bacon meal (0.5 g protein/kg body weight)
Study: 3884747
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (greater than 100 mg/m2) by an eight-hour infusion
Study: 3884747
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (greater than 100 mg/m2) by a one-hour infusion
Study: 31103608
Drug: Metreleptin administration
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin administration (replacement doses)
Study: 31103608
Drug: Metreleptin administration
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin administration (escalating doses)
Study: 29349511
Drug: sham-treatment+SRP
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham-treatment+SRP
Study: 31230964
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula (HFNC) (45 L/min, FIO2 100%)
Study: 31230964
Drug: High-Flow Face
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Face Mask (HFFM) (15 L/min)
Study: 15315998
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy and exercise training (n = 46)
Study: 30810638
Drug: GTP (periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTP (periodontal and peri-implant maintenance therapy)
Study: 10492157
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg daily for 2 days)
Study: 10492157
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg daily for 21 days)
Study: 6752878
Drug: Pirprofen 200
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirprofen 200 mg four times a day
Study: 6752878
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 900 mg four times a day
Study: 29929495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (one counseling session administered by a nurse)
Study: 23327030
Drug: bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine + fentanyl (7.5 mg of 0.5% bupivacaine + 15 microg fentanyl intrathecally)
Study: 23327030
Drug: levobupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine + fentanyl (7.5 mg of 0.5% levobupivacaine + 15 microg fentanyl intrathecally)
Study: 16258155
Drug: Real-time polymerase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time polymerase chain reaction (PCR) assay targeting 16S rDNA, limit of detection: 40, 50, or 2000 CFU/ml for E. coli, group B Streptococcus, and Listeria monocytogenes respectively, sample preparation and PCR duration less than 4 hours.
Study: 9951493
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TA) 75 mg/kg per day divided into 3 doses
Study: 9951493
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 0.75 mg/kg per day divided into 2 doses
Study: 7591596
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg/day) for 72 weeks
Study: 7591596
Drug: Prazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (4 mg/day) for 24 weeks
Study: 6246006
Drug: Mecillinam alone
Normalized name: mecillinam
DrugBank: Amdinocillin (DB01163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecillinam alone or in combination with ampicillin
Study: 6246006
Drug: Mecillinam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecillinam (5 mg/kg intravenously every six hours)
Study: 6246006
Drug: Mecillinam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecillinam (10 mg/kg intravenously every six hours)
Study: 6246006
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (mecillinam and ampicillin)
Study: 31074244
Drug: Nivolumab (PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (PD-1 inhibitor) administered every second week until disease progression
Study: 31467059
Drug: Nivolumab (PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (PD-1 inhibitor)
Study: 27125883
Drug: Mixed fibre
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed fibre (5 g b.d. for 4 weeks)
Study: 27125883
Drug: Psyllium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (5 g b.d. for 4 weeks)
Study: 15531619
Drug: Airflow via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airflow via sponge-tipped oxygen catheter at a rate of 115 ml kg(‐1) min(‐1) for 6 hours
Study: 12953342
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg bid for 3 days
Study: 12953342
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg qid
Study: 10971231
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and metronidazole 500 mg b.d. (PCM)
Study: 10971231
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg b.d., amoxycillin 1000 mg b.d., and clarithromycin 500 mg b.d. (PAC)
Study: 9011466
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU interferon-alpha2b every two days for another six months (group A, total dose: 410 MU)
Study: 9011466
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of interferon-alpha2b (6 MU every two days for three months, followed by 10 MU every two days for three months) (group B, total dose: 870 MU)
Study: 9011466
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU interferon-alpha2b every two days for three months (initial treatment)
Study: 30696903
Drug: Dihydroartemisinin-piperaquine with
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine with higher dosage and extended schedule (four monthly doses)
Study: 30696903
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage of dihydroartemisinin-piperaquine
Study: 24099152
Drug: Moxonidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.6 mg/day
Study: 19367282
Drug: Lomeguatrib 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomeguatrib 40 mg, b.i.d. for 10 days with temozolomide 75 mg m(‐2) on days 1‐5
Study: 19367282
Drug: Lomeguatrib extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomeguatrib extended dosing
Study: 15823785
Drug: Imaginative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaginative and hypnotic suggestions
Study: 15823785
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered after suggestions)
Study: 12516678
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral-B 35)
Study: 9595919
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 micrograms/day for three weeks with MAP 10 mg orally for 10 days
Study: 678495
Drug: 3.0% levamisole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0% levamisole solutions
Study: 678495
Drug: 3.0% mebendazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0% mebendazole suspensions
Study: 25158710
Drug: High-dose-rate brachytherapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate brachytherapy (2 × 6 Gy administered in two fractions: first within 4 hours after surgery and second within 24 hours)
Study: 25158710
Drug: High-dose-rate brachytherapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate brachytherapy
Study: 22067244
Drug: Control Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Condition (CC) - 5 minutes of passive rest
Study: 15381932
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg m(‐2) irinotecan as a 90‐min i.v. infusion q3 weeks (Arm A)
Study: 15381932
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg m(‐2) irinotecan as a 90‐min i.v. infusion weekly x 4 weeks q6 weeks (Arm B)
Study: 15381932
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg m(‐2) irinotecan as a 90‐min i.v. infusion q2 weeks (Arm C)
Study: 15381932
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg m(‐2) day(‐1) irinotecan as a 14‐day continuous infusion q3 weeks (Arm D)
Study: 11118782
Drug: Systematic education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic education using a self‐conducted, interactive Kodak Photo‐CD program plus personal drug information and non‐commercial drug leaflets.
Study: 9829706
Drug: DFMO 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO 0.5 g/m2/day
Study: 2687688
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg every six hours)
Study: 31904995
Drug: Energy-dense nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-dense nutrition (1.5 kcal/ml)
Study: 30346225
Drug: Routine enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine enteral nutrition (1.0 kcal/ml)
Study: 30513266
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cleansed adjacent to injection site)
Study: 27670267
Drug: Minocycline 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 3 mg/mL plus EDTA 30 mg/mL (M-EDTA)
Study: 27670267
Drug: Heparin 1000
Normalized name: HEPARIN 10000UNIT/ML CARPUJECT 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 1000 IU/mL (H)
Study: 26370664
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives prescribed to the control group with follow-up visit advised.
Study: 18380203
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% aluminum chloride (AC)
Study: 9075480
Drug: p24-VLP (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: p24-VLP (highest dose)
Study: 8396320
Drug: Oral acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acyclovir, 800 mg four times daily
Study: 8396320
Drug: Oral acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acyclovir, 800 mg four times daily + IVIG, 300 mg/kg every 2 weeks for six doses
Study: 11280632
Drug: Intracatheter nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracatheter nitroglycerin (NTG) infusion at 0.1 mcg x kg x min in 5% dextrose
Study: 29337906
Drug: Specific collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific collagen peptides (SCP) 5 g daily for 12 months
Study: 24641790
Drug: QiShenYiQi dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: QiShenYiQi dripping pills, Tongxinluo placebo and routine medication
Study: 24641790
Drug: Tongxinluo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo capsules, QiShenYiQi placebo and routine medication